TuHURA BIOSCIENCES, INC./NV Finance Lease, Liability, to be Paid, Year Two
TuHURA BIOSCIENCES, INC./NV (HURA) had Finance Lease, Liability, to be Paid, Year Two of $25.98 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo · last filed 2026-08-14
- 2026-06-30: Finance Lease, Liability, to be Paid, Year Two $25.98K.
- 2026-03-31: Finance Lease, Liability, to be Paid, Year Two $25.98K.
- 2025-12-31: Finance Lease, Liability, to be Paid, Year Two $51.97K.
- 2025-09-30: Finance Lease, Liability, to be Paid, Year Two $51.97K.
| Period end | Finance Lease, Liability, to be Paid, Year Two |
|---|---|
| 2026-06-30 | $25.98K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $25.98K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $51.97K 10-K · filed 2026-03-31 |
| 2025-09-30 | $51.97K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |